Intelligence Feed event · Policy · 2026-09-19

    Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization

    Question

    Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization

    Direct answer

    Teva Pharmaceutical Industries published real-world evidence indicating that UZEDY (risperidone) extended-release injectable suspension achieved higher patient adherence and persistence compared with alternative long-acting injectables in schizophrenia patients. The analysis indicated a measurable decline in emergency room interventions and aggregate healthcare expenses in bipolar I disorder cohorts. Commercial persistence metrics provide support for Teva's specialty branded pharmaceutical franchise revenue projections.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/teva-real-world-data-shows-uzedy-lowers-emergency-healthcare-utilization-37122f

    POLICY
    Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization
    Teva Pharmaceutical Industries published real-world evidence indicating that UZEDY (risperidone) extended-release injectable suspension achieved higher patient adherence and persistence compared with alternative long-acting injectables in schizophrenia patients. The analysis indicated a measurable decline in emergency room interventions and aggregate healthcare expenses in bipolar I disorder cohorts. Commercial persistence metrics provide support for Teva's specialty branded pharmaceutical franchise revenue projections.
    TEVA
    Impact
    58
    SEP 19
    SIG
    84%
    TEVA
    Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization
    Teva Pharmaceutical Industries published real-world evidence indicating that UZEDY (risperidone) extended-release injectable suspension achieved higher patient adherence and persistence compared with alternative long-acting injectables in schizophrenia patients. The analysis indicated a measurable decline in emergency room interventions and aggregate healthcare expenses in bipolar I disorder cohorts. Commercial persistence metrics provide support for Teva's specialty branded pharmaceutical franchise revenue projections.
    → Demonstrated reduction in hospital utilization strengthens payer formulary positioning and commercial adoption for TEVA specialty therapeutics.
    Impact
    Teva Pharmaceutical Industries published real-world evidence indicating that UZEDY (risperidone) extended-release injectable suspension achieved higher patient adherence and persistence compared with alternative long-acting injectables in schizophrenia patients. The analysis indicated a measurable decline in emergency room interventions and aggregate healthcare expenses in bipolar I disorder cohorts. Commercial persistence metrics provide support for Teva's specialty branded pharmaceutical franchise revenue projections.
    Affected
    TEVA
    Transmission
    Demonstrated reduction in hospital utilization strengthens payer formulary positioning and commercial adoption for TEVA specialty therapeutics.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TEVAspecialty brand revenue growth via commercial payer formulary placementUp1-3mReal-world data showed UZEDY outperformed alternative long-acting injectables in continuity and reduced emergency costs.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month